Ambroxol for treatment of liver cirrhosis and portal hypertension in Gaucher disease: A case report

[1]	CARUBBI F, CAPPELLINI MD, FARGION S, et al. Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist[J]. Dig Liver Dis, 2020, 52(4): 368-373. DOI: 10.1016/j.dld.2020.01.004.
[2]	NASCIMBENI F, CASSINERIO E, DALLA SALDA A, et al. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease[J]. Mol Genet Metab, 2018, 125(1-2): 64-72. DOI: 10.1016/j.ymgme.2018.08.004.
[3]	DEBNATH CR, DEBNATH MR, NABI N, et al. A case of Gaucher's disease progressing to liver cirrhosis[J]. Mymensingh Med J, 2013, 22(2): 394-396. http://www.ncbi.nlm.nih.gov/pubmed/23715368
[4]	ZIMRAN A, ALTARESCU G, ELSTEIN D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease[J]. Blood Cells Mol Dis, 2013, 50(2): 134-137. DOI: 10.1016/j.bcmd.2012.09.006.
[5]	PAWLINSKI L, KRAWCZYK M, FIEMA M, et al. Dual-action ambroxol in treatment of chronic pain in Gaucher disease[J]. Eur J Pain, 2020, 24(5): 992-996. DOI: 10.1002/ejp.1538.
[6]	HAN TU, SAM R, SIDRANSKY E. Small molecule chaperones for the treatment of gaucher disease and GBA1-associated parkinson disease[J]. Front Cell Dev Biol, 2020, 8: 271. DOI: 10.3389/fcell.2020.00271.
[7]	NGUYEN Y, STIRNEMANN J, BELMATOUG N. Gaucher disease[J]. Rev Prat, 2020, 70(4): 416-420.

Cited By

Figures(3)

Get Citation

PDF

XML

Article Metrics

Article views (634) PDF downloads(66)